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Background & Aims: Cyclooxygenase (COX)-2 is up-regu-
lated in most colonic cancers and in inflammatory bowel
disease in which tumor necrosis factor (TNF)-a is be-
lieved to play a central role. There has been recent
speculation on the activation of phosphatidylinositol
3-kinase (PI 3-kinase) by TNF-a and its role in the reg-
ulation of genes controlled by NF-kB. We investigated
the regulatory role of PI 3-kinase on COX-2 expression in
colonic epithelial cells. Methods: In HT-29 and Caco-2
colonic epithelial cells, COX-2 expression was induced by
either TNF-a or interleukin (IL)-1a as observed by North-
ern and Western analyses. COX-2 activity was assessed
by measuring prostaglandin E2 (PGE2) production by
enzyme-linked immunosorbent assay. NF-kB binding ac-
tivity was assessed by electrophoretic mobility shift as-
say. PI 3-kinase activity was measured by quantifying
the accumulation of PI 3-kinase–dependent D-3 lipid
products by high-performance liquid chromatography.
Results: The PI 3-kinase inhibitor wortmannin up-regu-
lated induced COX-2 expression in a concentration-
dependent manner in both HT-29 and Caco-2 cells. An
alternative PI 3-kinase inhibitor, LY294002, caused up-
regulation of induced COX-2 messenger RNA (mRNA) in
HT-29 cells at concentrations of <1 mmol/L. IL-4 and
IL-13, which are known to activate PI 3-kinase, down-
regulated HT-29 COX-2 mRNA, protein, and PGE2 pro-
duction. NF-kB binding activity was unaltered by PI 3-ki-
nase inhibition in HT-29 cells, in which TNF-a was shown
to activate PI 3-kinase directly. Conclusions: COX-2 is
negatively regulated by PI 3-kinase; we propose that the
inhibitory effect of IL-4 and IL-13 is mediated via a PI
3-kinase–dependent pathway. This mechanism does not
appear to involve NF-kB because PI 3-kinase inhibition
did not alter NF-kB binding activity. TNF-a can activate
PI 3-kinase directly in addition to inducing COX-2.
Cyclooxygenase (COX), the enzyme that synthesizesprostaglandins (PGs), was discovered in the 1970s
with its importance being immediately apparent as the
site of action of the nonsteroidal anti-inflammatory drugs
(NSAIDs), whose efficacy in inflammation had been
known of for decades.1 In 1991, COX was shown to have
2 isoforms that are classically understood as being the
constitutive component, COX-1, and the inducible com-
ponent, COX-2.2,3 In applying this knowledge to the
lower gastrointestinal tract, COX-2 has been shown to
be overexpressed in inflammatory bowel disease (IBD)4,5
and most colorectal adenomas and adenocarcinomas.6 In
IBD, increased levels of PGs such as PGE2 have been
shown in the diarrhea of those with active disease.7
Interestingly, however, NSAIDs cause clinical exacerba-
tion in the disease process8 and specific COX-2 inhibi-
tion causes deterioration in animal models of colitis.9
Furthermore, homozygous COX-2 2/2 knockout mice
are more susceptible to dextran sodium sulfate–induced
colitis, again implying a protective action of COX-2.10
In colorectal carcinomas, NSAIDs show a beneficial ef-
fect, with nonspecific COX inhibition causing a regres-
sion in adenomas, first described in familial adenomatous
polyposis coli with sulindac,11 and long-term aspirin use
being associated with a decreased incidence of colorectal
carcinoma.12,13
Tumor necrosis factor (TNF)-a and interleukin (IL)-1
are T helper (Th) 1 cytokines whose expression is in-
creased in IBD.14,15 The importance of TNF-a in Crohn’s
disease was shown recently by the significant beneficial
actions of its blockade by specific chimeric monoclonal
antibodies.16 Both cytokines independently activate the
nuclear factor–kB (NF-kB) transcription factor, which
causes activation of a number of proinflammatory genes
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such as IL-8 and inducible nitric oxide synthase
(iNOS).17 TNF-a activation of COX-2 in the colonic
epithelial cell line HT-29 was shown to be completely
dependent on NF-kB.18 Recent evidence shows that
TNF-a can activate the lipid kinase phosphatidylinositol
3-kinase (PI 3-kinase) directly in nongastrointestinal
systems.19–21 Furthermore, it is proposed that activation
of NF-kB involves PI 3-kinase and its downstream ef-
fector protein kinase B (PKB or Akt), although the
precise mechanistic pathways remain contentious,22,23
with conflicting evidence further confusing the issue.24
Phosphatidylinositol 3-kinases (PI 3-kinases) are a family
of enzymes that phosphorylate the 39-hydroxyl group of the
inositol ring of phosphoinositides. There are 3 classes, and
the prototypical class IA consists of a heterodimer of a
catalytic p110 subunit linked with a regulatory p85 sub-
unit that mediates activation via tyrosine kinase–coupled
transmembrane receptors. The related class IB enzyme is
activated by Bg subunits of heterotrimeric G proteins and
is thought to be mainly expressed in leukocytes. They
generate 3 D-3 phosphatidylinositol lipid products: phos-
phatidylinositol-(3)-monophosphate (PtdIns(3)P); phospha-
tidylinositol-(3,4)-bisphosphate (PtdIns(3,4)P2); and phos-
phatidylinositol-(3,4,5)-trisphosphate (PtdIns(3,4,5)P3).
We have shown that the Th2 cytokine IL-13 activates PI
3-kinase in intestinal epithelial cells,25 and other investiga-
tors have shown that IL-4 has a similar effect.26–28
PI 3-kinase–derived lipid products represent an im-
portant group of second messengers with various effects
including increasing cellular proliferation and cell sur-
face receptor trafficking.29 The effect on cellular prolif-
eration is clearly seen in the context of the PTEN (phos-
phatase and tensin homologue deleted on chromosome
10) tumor-suppressor gene. The PTEN gene product is
a phosphatase and converts the PI 3-kinase product
PtdIns(3,4,5)P3 to PtdIns(4,5)P2, thus inactivating
it.30–32 When PTEN is deleted or inactivated in humans,
there is an increase in PtdIns(3,4,5)P3; the result is a
variety of related cancer syndromes such as Cowden
syndrome. These syndromes are linked by the presence of
gastrointestinal hamartomatous polyps in their pheno-
type as well as other manifestations peculiar to each
syndrome.33–35 Furthermore, total PI 3-kinase activity
has been shown to be increased in sporadic colorectal
carcinoma tissue compared with adjacent normal muco-
sa.36 In contrast, mice lacking the p110g catalytic sub-
unit of class Ib PI-3 kinase developed colorectal carcino-
mas,37 but this does not appear to be seen by other
groups using a similar construct.38
The study of the action of these PI 3-kinase products
is facilitated by the availability of specific PI 3-kinase
inhibitors, in particular the fungal metabolite wortman-
nin39,40 and the structurally unrelated synthetic querce-
tin derivative LY294002.41 Wortmannin covalently at-
taches to the p110 catalytic subunit and causes
irreversible inhibition with a Ki of 1–10 nmol/L and a
similar IC50. LY294002 is structurally distinct from
wortmannin and acts as a competitive inhibitor for the
adenosine triphosphate binding site of PI 3-kinase and
has been shown to cause specific inhibition with a Ki of
1.6 mmol/L and an IC50 of 1.4 mmol/L.
This study demonstrates for the first time that PI
3-kinase has a regulatory effect on COX-2. Hence, use of
PI 3-kinase inhibitors results in marked up-regulation of
TNF-a–stimulated COX-2 messenger RNA (mRNA)
and protein expression as well as increased PGE2 produc-
tion, a major product of COX-2 activity. Similar effects
of PI 3-kinase inhibitors are observed on IL-1–stimulated
COX-2 expression in 2 independent cell lines. PI 3-ki-
nase activity appears to suppress COX-2 levels; this is
supported by the observation that the Th2 cytokines
known to activate PI 3-kinase, IL-4 and IL-13, down-
regulate COX-2 expression and activity. Furthermore,
this increase of COX-2 expression by PI 3-kinase inhi-
bition does not seem to be mediated by altered NF-kB
binding activity. Finally, given that TNF-a activates
PI 3-kinase, as evidenced by D-3 phosphatidylinositol
lipid accumulation, we propose a negative autoregula-




Human recombinant IL-13 and TNF-a (specific activ-
ity, 6 3 107 U/mg) were kindly provided by Dr. A Minty
(Sanofi Elf Bio Recherches, Laberges, France) and Glaxo
(Greenford, England), respectively. Human recombinant IL-
1a, IL-4, and IL-10 were purchased from Peprotech (London,
England). Two complementary DNAs for COX-2 were used
(Oxford Biomedical Research, Oxford, MI, and Cayman
Chemicals, Ann Arbor, MI) and shown to be equivalent with
regard to specificity. These were labeled with [a-32P]deoxycy-
tidine 59 triphosphate (Amersham Life Sciences, UK) by ran-
dom priming incorporation using High Prime (Roche Diag-
nostics, Lewes, England). Goat COX-2 immunoglobulin (Ig)
G antibody was purchased from Santa Cruz Biotechnology
(Santa Cruz, CA), and [32P]orthophosphoric acid (185 MBq/
mL) was obtained from DuPont NEN, Stevenage, UK. All
other reagents were from Sigma (Poole, England).
Cell Culture
The human colonic epithelial carcinoma cell line
HT-29 was obtained from the European Collection of Animal
Cell Cultures (ECACC) and American Type Culture Collection
(ATCC). Cells were cultured in humidified incubators at 37°C
and 5% CO2. HT-29 cells were cultured in McCoys 5A
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medium, and Caco-2 cells were cultured in minimal essen-
tial medium supplemented with 1% nonessential amino
acids and 2 mmol/L L-glutamine. Both media were supple-
mented with 10% fetal bovine serum, 10 U/mL penicillin/
streptomycin, and 10 mg/mL fungizone. The cells were
passaged weekly and, when confluent, were washed and
cultured in fresh medium without fetal bovine serum for 24
hours before stimulation. Growth-arrested cells were treated with
the appropriate concentrations of stimuli in medium without
serum and incubated as described above. Cell counting and via-
bility were checked by trypan blue exclusion at the beginning and
end of each experiment using representative wells and was always
.95%.
Cell Lysis
HT-29 cells (107/mL) were stimulated and incubated
at 37°C in McCoys medium as indicated. Reactions were
terminated by addition of 1 mL ice-cold lysis buffer (1%
[vol/vol], Nonidet P-40, 150 mmol/L NaCl, 50 mmol/L Tris
[pH 7.5], 5 mmol/L EDTA, 10 mmol/L sodium fluoride,
1 mmol/L phenylmethylsulfonyl fluoride, 10 mg/mL leupep-
tin, 10 mg/mL aprotinin, 1 mg/mL soybean trypsin inhibitor,
1 mg/mL pepstatin A, 1 mmol/L sodium orthovanadate, and 1
mmol/L sodium molybdate). Lysates were incubated at 4°C for
15 minutes, followed by centrifugation at 14,000 rpm. A
Bradford Protein Assay (Bio-Rad reagents, Bio-rad Laborato-
ries, Hercules, CA) was then performed on the supernatants.
Western Analysis for COX-2 Protein
Equalized aliquots of cell lysate supernatant were boiled
in Laemmli buffer and electrophoresed through 7.5% (vol/vol)
acrylamide gels (with an acrylamide:bis-acrylamide ratio of
37.5:1) by sodium dodecyl sulfate–polyacrylamide gel electro-
phoresis (SDS-PAGE). The proteins were transferred by electrob-
lotting onto nitrocellulose (Schleicher & Schuell, London, UK) as
described previously.25 The blots were probed with an anti—
COX-2 goat IgG antibody (1 mg/mL), and proteins were visual-
ized by enhanced chemiluminescence with a rabbit anti-goat Ig
(0.1 mg/mL) conjugated with horseradish peroxidase as the sec-
ondary antibody.
Northern Analysis for COX-2 RNA
Total cellular RNA was isolated using RNAsol B.
The concentration of RNA was measured by obtaining the
absorbance at 260 and 280 nm, and 10 mg of RNA was
loaded into each well of the agarose gel. Total RNA was
separated using formaldehyde, 1% agarose gels, and trans-
ferred overnight to nylon membrane by capillary blotting.
Blots were baked for 20 minutes at 120°C, prehybridized
for an hour, and then hybridized with the 32P-labeled
COX-2 probe in high-SDS hybridization solution (7% SDS,
0.1 mmol/L EDTA, and 0.25 mol/L Na2HPO4 , pH 7.2) at
63°C overnight as described previously.42 Membranes were
washed twice for 5 minutes with 63 SSPE (NaCL 0.15
mol/L, NaH2PO4 0.01 mol/L, EDTA 1 mmol/L) plus 0.1%
SDS at 37°C, twice for 15 minutes with 13 SSPE plus
0.1% SDS at 37°C, and in 2 high-stringency washes at
63°C with 23 SSPE, 0.1% SDS for 5 minutes. Bound probe
was quantified with a phosphorimager (Molecular Dynam-
ics, Sunnyvale, CA). Equivalent amounts of total RNA load
per gel lane were assessed by stripping the membranes and
reprobing for b-actin, as previously described using a
digoxigenin-labeled oligonucleotide probe visualized with
antidigoxigenin Fab fragments conjugated to alkaline phos-
phatase with lumigen CSPD as chemiluminescent substrate
(all Roche) and also by monitoring 18S and 28S RNA.43
Membranes were stripped by washing twice in 0.1% SDS at
100°C while cooling to room temperature.
D-3 Phosphatidylinositol Lipid Labeling,
Extraction, and High-Performance Liquid
Chromatography Separation
HT-29 cells were labeled with 37 MBq [32P]
orthophosphate (185 MBq/mL; DuPont NEN), aliquoted at
107 cells/120 mL, and stimulated as outlined in the figure
legends. Phospholipids were extracted with 750 mL chloro-
form:methanol:H2O (32.6:65.3:2.1%, vol/vol/vol) as previ-
ously described. The samples were deacylated and analyzed by
anion exchange high-performance liquid chromatography
analysis using a partisphere SAX column (Whatman, Maid-
stone, UK). The eluate was fed into a Canberra Packard A-500
Flo-One on-line radiodetector (Maidstone, UK), and the re-
sults were analyzed by the Flo-One data program (Radio-
matic). Eluted peaks were compared with retention times for
standards prepared from 3H-labeled phophatidylinositol lipids
(Amersham) and 32P-labeled D-3 phosphatidylinositols as de-
scribed previously.44
PGE2 Enzyme-Linked Immunosorbent Assay
PGE2 was assayed using a commercially available en-
zyme-linked immunosorbent assay (ELISA) from R&D systems
(Abingdon, England), following the manufacturer’s guidelines
on triplicate cell culture supernatants stimulated for 24 hours
as described. The results were statistically analyzed using
analysis of variance (ANOVA), with Dunnett’s correction
where necessary, and are presented as mean 6 standard error of
the mean (SEM).
Nuclear Extracts and Electrophoretic
Mobility Shift Assay
HT-29 cells (1 3 106) were grown in 60-mm plates
and, at 80% confluency, were stimulated with TNF-a (5
ng/mL) or IL-1 (5 ng/mL) with or without pretreatment with
wortmannin (100 nmol/L) or LY294002 (25 mmol/L) for 30
minutes. Nuclear extracts were prepared as described previ-
ously.45 Extracts (5 mg) were incubated with radiolabeled
double-stranded class I major histocompatibility complex kB
sites (GGCTGGGGATTCCCCATCT), separated by nondena-
turing electrophoresis, and analyzed by autoradiography as
described previously.45
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Results
TNF-a–Induced COX-2 mRNA, Protein, and
PGE2 Production, Are Up-regulated by the
PI 3-Kinase Inhibitor Wortmannin
TNF-a stimulated concentration-dependent up-
regulation of COX-2 mRNA in HT-29 cells compared
with unstimulated controls, which showed no detectable
COX-2 mRNA expression (Figure 1A ). HT-29 cells
pretreated with the PI 3-kinase inhibitor wortmannin for
15 minutes before addition of TNF-a exhibited mark-
edly enhanced COX-2 mRNA expression in a concen-
tration-dependent manner (1–100 nmol/L) (Figure 2A ).
Addition of wortmannin had no effect in the absence of
cytokine stimulation (Figure 2B).
Having established that TNF-a–induced COX-2
mRNA expression is markedly up-regulated by wort-
mannin, we next evaluated whether similar effects were
observed at the level of protein expression. Western blot
analysis, using a specific anti–COX-2 antibody, showed
that TNF-a up-regulated COX-2 protein expression
compared with control unstimulated cells (Figure 1C ).
Moreover, wortmannin enhanced the TNF-a–stimulated
COX-2 protein expression in a concentration-dependent
manner (Figure 2C ).
Given that TNF-a stimulated up-regulation of
COX-2 expression at the mRNA and protein level, we
next investigated the effect of TNF-a on COX-2 enzyme
activity as assessed by production of one of its metabolic
products, PGE2. Wortmannin caused significant concen-
tration-dependent up-regulation of TNF-a–induced
PGE2 production, correlating with the findings for
mRNA and protein (Figure 2D).
PI 3-Kinase Inhibitors Potentiate IL-1a—
induced COX-2 Expression
To investigate whether the effects of PI 3-kinase
inhibition on induced COX-2 were unique to the TNF-a
stimulation or to wortmannin, we used a different in-
ducer of COX-2 as well as a structurally distinct PI
3-kinase inhibitor, LY294002. In HT-29 cells, IL-1a
can induce COX-2 mRNA in a concentration-dependent
manner compared with unstimulated controls (Figure
1B). Furthermore, it can induce COX-2 protein, al-
though not as potently as TNF-a (Figure 1C ). As with
TNF-a, in cells pretreated with the PI 3-kinase inhibitor
wortmannin for 15 minutes before the addition of IL-1a,
COX-2 mRNA expression in response to IL-1a was
markedly enhanced in a concentration-dependent man-
ner (1–100 nmol/L) (Figure 3A ). A similar effect was
observed with the potentiation of IL-1a–induced COX-2
protein by wortmannin at 100 nmol/L (Figure 3B), but
an effect on PGE2 could not be assessed because IL-1a
does not induce significant measurable PGE2 production.
Having demonstrated that the effect of PI 3-kinase
inhibition with wortmannin on COX-2 induction is
independent of stimulating cytokine, we next evaluated
whether a structurally distinct PI 3-kinase inhibitor,
LY294002, would also result in up-regulation of induced
COX-2. HT-29 cells pretreated with LY294002 for 30
minutes before addition of either IL-1a or TNF-a re-
sulted in enhanced COX-2 mRNA expression at concen-
trations ,1 mmol/L (Figure 4A and B). Above this
concentration, there was inhibition of COX-2 induction
by either IL-1a or TNF-a, resulting in near complete
inhibition at 10 mmol/L. LY294002 (1 and 3 mmol/L)
treatment without cytokines had no effect on COX-2
mRNA induction (Figure 4C ).
Figure 1. Up-regulation of COX-2 expression by TNF-a and IL-1a. (A
and B) Northern analyses of mRNA isolated from HT-29 cells that were
exposed to increasing concentrations of (A) TNF-a (1–100 ng/mL) or
(B) IL-1a (0.3–30 ng/mL) for 2 hours and probed for COX-2 (upper
panels). Membranes were stripped and reprobed for b-actin to dem-
onstrate loading (lower panels). Lane C represents an unstimulated
control sample. (C) Western analysis of protein isolated from HT-29
cells exposed to either TNF-a (100 ng/mL) or IL-1a (10 ng/mL) for 6
hours compared with an unstimulated control sample and probed with
a specific anti–COX-2 antibody. Blots are from single experiments but
are representative of at least 3 others.
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IL-4 and IL-13, but not IL-10, Inhibit TNF-a–
Induced COX-2 Expression
Having shown that PI 3-kinase inhibition
causes up-regulation of COX-2 independent of stim-
ulus, we hypothesized that activation of PI 3-kinase
would inhibit COX-2 induction. The Th2 cytokines
IL-4 and IL-13 are known to induce PI 3-kinase and
would, therefore, be expected to down-regulate in-
duced COX-2. HT-29 cells pretreated with IL-4, IL-
10, and IL-13 (all at 30 ng/mL for 1 hour) before
stimulation with TNF-a showed that IL-4 and IL-13,
but not IL-10, caused significant inhibition of TNF-
a–induced COX-2 mRNA (Figure 5A ).
We have demonstrated that IL-4 and IL-13 have a
marked inhibitory action on TNF-a–induced COX-2
mRNA; we therefore evaluated whether similar effects
were observed at the level of protein expression. Western
blot analysis, using a specific anti–COX-2 antibody,
showed that IL-4 and IL-13 again caused a marked
inhibition of TNF-a–induced COX-2 protein, with
IL-10 having no effect (Figure 5B).
We further investigated what action these cytokines
had on COX-2 enzyme activity as assessed by PGE2
Figure 2. Up-regulation of TNF-a–induced COX-2 expression by wortman-
nin. (A) Northern analysis of mRNA isolated from HT-29 cells that were
stimulated with TNF-a (100 ng/mL) for 2 hours and pretreated with
increasing concentrations of the PI 3-kinase inhibitor wortmannin (0–100
nmol/L) for 15 minutes in the dark, and probed for COX-2 (upper panel).
The membrane was stripped and reprobed for b-actin to demonstrate
loading (lower panel). (B) Northern analysis of mRNA from HT-29 cells
treated with TNF-a (100 ng/mL) for 2 hours compared with an unstimu-
lated control and wortmannin treatment alone (10 and 100 nmol/L) and
probed for COX-2 (upper panel). The membrane was stripped and re-
probed for b-actin to demonstrate loading (lower panel). (C) Western
analysis of protein isolated from HT-29 cells that were stimulated with
TNF-a (100 ng/mL) for 6 hours, pretreated with wortmannin (0–100
nmol/L), and probed with a specific anti–COX-2 antibody. (D) ELISA for
PGE2 (pg/mL) using supernatants from HT-29 cells stimulated with TNF-a
(100 ng/mL) for 24 hours and pretreated with wortmannin (0–100
nmol/L). *P , 0.05 and **P , 0.01, significant increases in PGE2
production by additional wortmannin pretreatment compared with TNF-a
alone. Results are from 1 experiment using triplicate samples and are
representative of 3 other experiments. C, unstimulated control samples.
Blots are from single experiments but are representative of at least 3
others.
Figure 3. Up-regulation of IL-1a–induced COX-2 expression by wort-
mannin. (A) Northern analysis of mRNA isolated from HT-29 cells
that were stimulated with IL-1a (10 ng/mL) for 2 hours, pretreated
with increasing concentrations of the PI 3-kinase inhibitor wortman-
nin (0–100 nmol/L) for 15 minutes in the dark, and probed for
COX-2 (upper panel). The membrane was stripped and reprobed for
b-actin to demonstrate loading (lower panel). Lane C represents an
unstimulated control sample. (B) Western analysis of protein iso-
lated from HT-29 cells stimulated for 6 hours with IL-1a (10
ng/mL), pretreated with wortmannin (100 nmol/L), and probed
with a specific anti–COX-2 antibody. Blots are from single experi-
ments but are representative of at least 3 others.
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production. Again IL-4 and IL-13 were shown to signif-
icantly inhibit TNF-a–induced PGE2 production. The
effect of IL-10 was not significant (Figure 5C ).
TNF-a and IL-1a Stimulate NF-kB
Independently of PI 3-Kinase Activation
It has been shown that COX-2 induction in
HT-29 cells is completely dependent on activation of the
transcription factor NF-kB.18 In view of PI 3-kinase
inhibition causing an up-regulation of COX-2 induction
at the mRNA, protein, and product level, we investi-
gated whether this was caused by increased NF-kB ac-
tivation. TNF-a and IL-1a are both known to activate
NF-kB in HT-29 cells; this was demonstrated in the
Figure 5. Regulation of COX-2 expression by Th2 cytokines. (A) North-
ern analysis of mRNA isolated from HT-29 cells that were stimulated
with TNF-a (100 ng/mL) for 2 hours; pretreated with IL-4, IL-10, or
IL-13 (all at 30 ng/mL) for 1 hour; and probed for COX-2 (upper panel).
The membrane was stripped and reprobed for b-actin to demonstrate
loading (lower panel). (B) Western analysis of protein isolated from
HT-29 cells stimulated for 6 hours with TNF-a (100 ng/mL); pretreated
with IL-4, IL-10, or IL-13; and probed with a specific anti–COX-2
antibody. (C) ELISA for PGE2 (pg/mL) using supernatants from HT-29
cells stimulated with TNF-a (100 ng/mL) for 24 hours and pretreated
with IL-4, IL-10, or IL-13. **P , 0.05, significant inhibition. Results
are from 1 experiment using triplicate samples, representative of 3
other experiments. C, unstimulated controls. Blots are from single
experiments but are representative of at least 3 others.
Figure 4. Concentration-dependent effects of LY294002 on induced
COX-2 expression. (A and B) Northern analyses of mRNA isolated from
HT-29 cells exposed for 2 hours to (A) IL-1a (10 ng/mL) or (B) TNF-a
(100 ng/mL), pretreated with increasing concentrations of the PI
3-kinase inhibitor LY294002 (0–10 mmol/L) for 30 minutes, and
probed for COX-2 (upper panels). Membranes were stripped and
reprobed for b-actin to demonstrate loading (lower panels). (C) North-
ern analysis of TNF-a (100 ng/mL)–induced COX-2 mRNA at 2 hours
compared with an unstimulated control and LY294002 treatment
alone (1 and 3mmol/L) (upper panel). The membrane was stripped
and reprobed for b-actin to demonstrate loading (lower panel). C,
unstimulated control samples. Blots are from single experiments but
are representative of at least 3 others.
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present study with TNF-a (5 ng/mL) having a greater
effect than IL-1a at the same concentration (Figure 6).
This activation was not altered by preincubation with the
2 PI 3-kinase inhibitors, wortmannin (100 nmol/L) or
LY294002 (25 mmol/L), both for 30 minutes.
IL-1a Induces COX-2 mRNA in Caco-2
Intestinal Epithelial Cells, Which Is
Up-regulated by the Wortmannin
To ensure that the regulatory role for PI 3-kinase
on COX-2 observed in HT-29 intestinal epithelial cells
was not specific to that model, we investigated COX-2
expression in the Caco-2 cell line. This cell line is also
derived from human colorectal carcinoma but is other-
wise independent with a distinguishable phenotype.46
Investigation in Caco-2 cells showed that IL-1a (10
ng/mL) was capable of inducing COX-2 mRNA, whereas
TNF-a (100 ng/mL) had only a minimal effect (data not
shown). Caco-2 cells pretreated with the PI 3-kinase
inhibitor wortmannin for 15 minutes before addition of
IL-1a exhibited markedly enhanced COX-2 mRNA ex-
pression in a concentration-dependent manner (10–100
nmol/L) (Figure 7).
TNF-a Activates PI 3-Kinase in HT-29 Cells
Recent studies show that TNF-a can activate PI
3-kinase directly in other cell systems.19–21 We tested
this in intestinal epithelial cells by stimulating 32P-
labeled HT-29 cells with TNF-a (100 ng/mL for 30
seconds) with or without wortmannin (100 nmol/L for
15 minutes in the dark). PI 3-kinase activation was
determined by measuring the accumulation of its prod-
ucts, the D-3 phosphatidylinositol lipids. The HT-29
intestinal epithelial cell line is known to have some
constitutive PI 3-kinase activity, which is reflected in a
baseline amount of PtdIns(3,4)P2 production in the un-
stimulated control (Figure 8).25 Stimulation with TNF-a
resulted in a significant (P , 0.02) increase of
PtdIns(3,4)P2 , indicating further induction of PI 3-ki-
nase by TNF-a above the constitutive activity; this was
partially inhibited by pretreatment with wortmannin
(Figure 8).
Discussion
We used 2 independent intestinal epithelial cell
lines in this study and demonstrate for the first time that
Figure 6. Cytokine-induced NF-kB binding activity is not altered by PI
3-kinase inhibition. HT-29 cells were stimulated with TNF-a or IL-1a
(both at 5 ng/mL for 30 minutes) with or without 30-minute pretreat-
ment with 2 independent PI 3-kinase inhibitors, wortmannin (100
nmol/L) or LY294002 (25 mmol/L). Nuclear extracts (5 mg) were
tested for NF-kB binding activity by electrophoretic mobility shift as-
say. Pretreatment with PI 3-kinase inhibitors did not alter cytokine-
induced activation of NF-kB binding activity. Blot is from a single
experiment but is representative of at least 3 others.
Figure 7. Up-regulation of IL-1a–induced COX-2 expression by wort-
mannin in Caco-2 cells. (A) Northern analysis of mRNA isolated from
Caco-2 cells that were stimulated with IL-1a (10 ng/mL) for 2 hours,
pretreated with increasing concentrations of the PI 3-kinase inhibitor
wortmannin (0–100 nmol/L) for 15 minutes in the dark, and probed
for COX-2 (upper panel). The 28S band demonstrates loading (lower
panel). Lane C represents an unstimulated control sample. Blot is
from a single experiment but is representative of at least 3 others.
Figure 8. Activation of PI 3-kinase by TNF-a. Bar chart representing
accumulation of the 32P-labeled PI 3-kinase product, PtdIns(3,4)P2, as
isolated and quantified by high-performance liquid chromatography
(cpm). 32P-labeled HT-29 cells were stimulated with TNF-a (100 ng/L)
for 30 seconds in the presence or absence of pretreatment for 15
minutes in the dark with the PI 3-kinase inhibitor wortmannin (100
nmol/L). The controls represent unstimulated cells and cells treated
with wortmannin alone. **P , 0.02, significant activation of PI 3-ki-
nase by TNF-a.
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PI 3-kinase activity has a negative regulatory effect on
COX-2. We propose that this down-regulation acts as
the mechanism for the inhibitory effects of IL-4 and
IL-13 on COX-2, because they are known to activate PI
3-kinase. Furthermore, the mechanism of action for PI
3-kinase does not appear to involve NF-kB because its
binding activity is unaltered by PI 3-kinase inhibition.
Finally, we show that, in intestinal epithelial cells,
TNF-a activates PI 3-kinase and that this could act as a
negative autoregulatory feedback loop on the TNF-a
activation of COX-2 (Figure 9).
IL-1a induces COX-2 expression in both HT-29 and
Caco-2 cells, which was further increased by wortman-
nin, a PI 3-kinase inhibitor derived from a metabolite of
the fungus Penicillium fumiculosum Thom. This effect of
wortmannin correlates well with its Ki of 1–10 nmol/L.
Another PI 3-kinase inhibitor, LY294002, which is
structurally distinct from wortmannin and derived from
quercetin, also had an up-regulatory effect on COX-2
mRNA expression in HT-29 cells at concentrations
of #1 mmol/L. However, at higher concentrations,
LY294002 inhibited TNF-a– and IL-1a–induced
COX-2 mRNA expression; this is assumed to be a
nonspecific action. This assumption is supported by the
properties of LY294002 whose IC50 is 1.4 mmol/L and Ki
is 1.6 mmol/L. Thus, at concentrations up to 1 mmol/L,
LY294002 would be predicted to be exerting the specific
inhibitory effects on PI 3-kinase observed in this study.
Conversely, one might predict the actions of LY294002
observed at concentrations above the reported IC50 and Ki
values to be mediated via nonspecific actions of this
compound. The different response profiles for the 2 in-
hibitors may also be due to disparate effects on different
classes of the PI 3-kinase family of enzymes. For example,
wortmannin is a poor inhibitor of class II PI 3-kinases.47
Such effects of specific classes may well be important in
HT-29 cells in which differential class effects of PI
3-kinase enzymes are involved in controlling macroau-
tophagy48; this may also explain why wortmannin only
partially inhibits the TNF-a induction of PI 3-kinase
seen in Figure 8.
Th2 cytokines are known to have an immunoregula-
tory role and have been used with beneficial effects in
therapeutic trials of IBD in humans.49,50 IL-13 has been
shown to down-regulate RANTES (regulated upon acti-
vation, normal T cell expressed and secreted) and iNOS
in this system. The mechanism for the latter was shown
to be dependent on the activation of PI 3-kinase by
IL-13.25,43 IL-4 has been shown to activate PI 3-kinase in
other systems and has similar immunoregulatory effects
as IL-13 in intestinal systems, probably as a consequence
of shared receptors and signaling pathways.26–28 In the
present study, we show that IL-4 and IL-13 inhibit
COX-2 expression and activity and propose that this is
caused by their activation of PI 3-kinase, which has been
shown to have an inhibitory effect on COX-2. This is
technically difficult to prove further because we have
already shown that addition of PI 3-kinase inhibitors, to
abolish Th2 cytokine activation of PI 3-kinase, indepen-
dently increases COX-2 expression. That IL-10 was not
demonstrated to have an effect is not surprising in a
system that appears to be unable to respond to this
cytokine.43,51 IL-10 can bind IL-10 receptors on HT-29
cells, although these receptors may lack the intracellular
portion necessary to mediate cell responses.51 Th2 cyto-
kines have been reported to inhibit COX-2 expression in
various systems, including osteoblasts52 and mono-
cytes,53 with a variety of mechanistic pathways having
been proposed.53–55 These mechanisms are not mutually
exclusive and do not exclude the upstream involvement
of PI 3-kinase. Indeed, because activation of PI 3-kinase
is an almost immediate effect, with significant activation
within 30 seconds for IL-1325 and TNF-a, it seems likely
that PI 3-kinase is the first step of a mechanistic pathway
that alters downstream signaling cascades or the tran-
scription and stability of COX-2 RNA. This is sup-
ported by the demonstration that LY294002 can alter
MAP kinase activation, a pathway known to be impor-
tant in COX-2 mRNA stability and transcription.56–59
Also, PKB, a downstream effector of PI 3-kinase, appears
to play a part in regulating COX-2 RNA stability in
intestinal epithelial cells.60
TNF-a was recently shown to activate PI 3-kinase in
HeLa cells,21 rat fibroblasts,20 cervical epithelial cells,22
and embryonic kidney cells,22 although the biological
implications of this are uncertain. Also, TNF-a activa-
tion of NF-kB can be PI 3-kinase dependent.61 Despite
these observations, some reports show that TNF-a acti-
Figure 9. Schematic of proposed pathways regulating COX-2 in intes-
tinal epithelial cells based on the findings of this study. Note that
TNF-a activates both NF-kB–dependent COX-2 induction and also PI
3-kinase, which will have an inhibitory effect. However, the overall
effect is activation of COX-2.
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vation of NF-kB can occur independently of PI 3-ki-
nase.57 COX-2 expression is completely dependent on
NF-kB in HT-29 cells,18 but the present findings show
that PI 3-kinase inhibition increases COX-2 expression
and activity independent of any alteration of NF-kB
activity. Other investigators have shown NF-kB activity
in HT-29 cells to be altered by PI 3-kinase inhibition,
but over a much longer time period with much higher
inhibitor concentration.24 We also show that TNF-a
does activate PI 3-kinase beyond the constitutive activity
that these cells are known to demonstrate. One interpre-
tation of our results is that this basal PI 3-kinase activity
may be regulating COX-2 expression. Against this, how-
ever, is the fact that neither PI 3-kinase inhibitor we
used had any effect on COX-2 mRNA or protein expres-
sion or on PGE2 production when used in the absence of
cytokine stimulation. Therefore, the regulatory effects of
PI 3-kinase on COX-2 expression we show depend on
cytokine induction of COX-2 that, in the case of TNF-a,
will also increase PI 3-kinase activity.
In intestinal epithelial cells, TNF-a is now known to
activate proapoptotic pathways, the NF-kB signaling
pathway as well as the proproliferative PI 3-kinase,62 as
we show in the present study. Making sense of these
conflicting intracellular signals highlights the multiple
controls of cellular responses with the overall outcome
representing the final balance of the divergent pathways.
Using this work as an example, we propose that the
TNF-a activation of PI 3-kinase will act as a negative
autoregulatory pathway on the TNF-a activation of NF-
kB–dependent COX-2 expression. Such autoregulatory
feedback loops are likely to be repeated many times in
the cell with the apparent redundancy of mechanisms
allowing better controlled and smoother cellular re-
sponses (Figure 9).
Applying these findings to disease processes raises
many questions. First, there is intense speculation on the
biological role of COX-2 in chronic inflammation.
COX-2 was initially considered a proinflammatory en-
zyme, but it is now realized that its biological function
can vary markedly with differential PG production oc-
curring over different time courses. The cyclopentenone
PGs, such as PGJ2 , have anti-inflammatory properties
mediated by peroxisome proliferator–activated receptor
g activation63 and are produced by COX-2 later than
PGE2.64 Indeed, these proposed beneficial products of
chronic COX-2 expression may be the reason why
NSAIDs aggravate IBD,8 why specific COX-2 inhibitors
aggravate animal models of colitis,9 and why COX-22/2
mice are more sensitive to chemically induced colitis
than COX-21/1 littermates.10 In our study, the Th2
cytokines, IL-4 and IL-13, down-regulated COX-2 ex-
pression, resulting in decreased COX-2 protein and
PGE2 levels. We propose that this is via a PI 3-kinase–
dependent mechanism. This in vitro system mimics
acute COX-2 production, which is generally agreed as
being proinflammatory, and this corresponds to the doc-
umented anti-inflammatory actions of these Th2 cyto-
kines. It will be interesting to see whether Th2 cytokines
have different regulatory effects on the proposed benefi-
cial cyclopentenone products of COX-2 such as PGJ2.
Finally, it has been hypothesized that the chronic
overexpression of COX-2 in IBD is the reason why this
population has an increased risk of colorectal carcino-
ma.4,65 PI 3-kinase is known to have a proproliferative
role; this is demonstrated by the fact that its levels are
increased in colorectal cancer36 and that the PTEN tu-
mor-suppressor gene is a 39-phosphatase involved in the
degradation of PI 3-kinase products.30,33,35 However, it
remains to be seen how the negative regulation of
COX-2 by PI 3-kinase correlates with the proposed
procarcinogenic potential of each.
In conclusion, our study represents the first demon-
stration of the involvement of PI 3-kinase in the regu-
lation of COX-2. The negative effect of PI 3-kinase
activity on COX-2 expression provides a possible mech-
anism for the Th2 cytokines, which are known to activate
PI 3-kinase and which down-regulate COX-2. The reg-
ulatory action of PI 3-kinase does not appear to involve
NF-kB, whose binding activity is unaltered by PI 3-ki-
nase inhibition. Finally, TNF-a is shown to activate PI
3-kinase in intestinal epithelial cells, demonstrating the
possible existence of a negative autoregulatory feedback
loop on TNF-a–induced COX-2 expression. This novel
work helps define the complex molecular mechanisms
involved in the regulation of intestinal epithelial COX-2
expression; these may act as therapeutic targets of the
future.
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